January 11, 2023
Otsuka Pharmaceutical and Lundbeck said on January 10 that the US FDA has accepted a supplementary new drug application (sNDA) for the atypical antipsychotic Rexulti (brexpiprazole) for use in the treatment of agitation associated with Alzheimer’s dementia. The application has...read more